MetaCap

Allogene Therapeutics (ALLO) vs Cabaletta Bio (CABA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Allogene Therapeutics (ALLO) has outperformed Cabaletta Bio (CABA) over the past year, losing 49.0% versus a loss of 55.0%. Over five years, CABA leads with a -91.9% price change compared with -96.5% for ALLO. Allogene Therapeutics is the larger company by market cap ($217.5 million vs $201.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLO-48.97%CABA-55.00%
+159%+47%-65%
Nov 21, 20251 yearNov 20, 2026
ALLO-96.66%CABA-92.19%
+119%+6%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLO versus CABA key metrics
MetricALLOCABA
Share price$0.6277$0.9361
Market cap$217.48M$201.94M
1-day change-5.88%-7.32%
YTD return-54.18%-57.26%
1-year return-48.97%-55.00%
5-year return-96.51%-91.93%
EPS (TTM)$-0.61$-1.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-190.89M$-167.86M
52-week high$4.46$4.23
52-week low$0.6192$0.93
Distance from 52-week high-85.93%-77.87%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1333.81%+1155.21%
Average volume7.69M5.15M
Shares outstanding346.47M215.72M
Employees150154
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Allogene Therapeutics

ALLO stock →

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees

About Cabaletta Bio

CABA stock →

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees

ALLO vs CABA FAQ

Which is bigger, Allogene Therapeutics or Cabaletta Bio?

Allogene Therapeutics (ALLO) is larger, with a market capitalization of $217.48M compared with $201.94M for Cabaletta Bio (CABA).

Which stock has performed better over the past year, ALLO or CABA?

ALLO returned -48.97% over the past 12 months, compared with -55.00% for CABA (price return, excluding dividends). Past performance does not predict future results.

Are Allogene Therapeutics and Cabaletta Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons